Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI)

Sürder, Daniel; Schwitter, Jürg; Moccetti, Tiziano; Astori, Giuseppe; Rufibach, Kaspar; Plein, Sven; Cicero, Viviana Lo; Soncin, Sabrina; Windecker, Stephan; Moschovitis, Aris; Wahl, Andreas; Erné, Paul; Jamshidi, Peiman; Maur, Christoph Auf der; Manka, Robert; Soldati, Gianni; Bühler, Ines; Wyss, Christophe; Landmesser, Ulf; Lüscher, Thomas F.; Corti, Roberto

doi:10.1016/j.ahj.2010.03.039

Cited by 78 publications

(47 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 In brief, patients with acute ST-segment elevation myocardial infarction (STEMI) and successful percutaneous coronary intervention within 24 hours after symptom onset were eligible for enrollment into this multicenter randomized controlled trial provided that they presented with an estimated LV ejection fraction (LVEF) of <45% as assessed by an LV angiogram or transthoracic echocardiography the day of or after the AMI. After giving their informed consent to participate in the study, patients were randomly assigned in a 1:1:1 fashion to 1 open labeled control and 2 BM-MNC treatment groups.…”

Section: Study Sample and Protocolmentioning

confidence: 99%

Intracoronary Injection of Bone Marrow–Derived Mononuclear Cells Early or Late After Acute Myocardial Infarction

Sürder¹,

Manka²,

Cicero³

et al. 2013

Circulation

Self Cite

181

117

View full text Add to dashboard Cite

Background-Intracoronary administration of autologous bone marrow-derived mononuclear cells (BM-MNC) mayimprove remodeling of the left ventricle (LV) after acute myocardial infarction. The optimal time point of administration of BM-MNC is still uncertain and has rarely been addressed prospectively in randomized clinical trials. Methods and Results-In a multicenter study, we randomized 200 patients with large, successfully reperfused ST-segment elevation myocardial infarction in a 1:1:1 pattern into an open-labeled control and 2 BM-MNC treatment groups. In the BM-MNC groups, cells were administered either early (ie, 5 to 7 days) or late (ie, 3 to 4 weeks) after acute myocardial infarction. Cardiac magnetic resonance imaging was performed at baseline and after 4 months. The primary end point was the change from baseline to 4 months in global LV ejection fraction between the 2 treatment groups and the control group. The absolute change in LV ejection fraction from baseline to 4 months was −0.4±8.8% (mean±SD; P=0.74 versus baseline) in the control group, 1.8±8.4% (P=0.12 versus baseline) in the early group, and 0.8±7.6% (P=0.

show abstract

Section: Study Sample and Protocolmentioning

confidence: 99%

Intracoronary Injection of Bone Marrow–Derived Mononuclear Cells Early or Late After Acute Myocardial Infarction

Sürder¹,

Manka²,

Cicero³

et al. 2013

Circulation

Self Cite

181

117

View full text Add to dashboard Cite

show abstract

“…The BOOST and the FINCELL trials further confirmed the significant improvement in LVEF by angiography in the stem cell treated groups [3,4]. By contrast, the latest HEBE trial completed in 2011, the Swiss-AMI trial and the ASTAMI trial reported similar or reduced effect of BMMNC therapy and the placebo [5][6][7]. Of note, in the HEBE trial, cells were processed for an undefined period of time and were delivered to patients in a heparin solution containing human serum albumin.…”

Section: Introductionmentioning

confidence: 80%

Ex-Vivo Expansion of Cardiac Stem Cell Therapy Products for Clinical Use: The Importance of Moving towards the Optimization of Process Development

Bardelli¹

2016

Int J Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…La non-univocità dei risultati dei vari trial è sicuramente imputabile alla conoscenza incompleta dei meccanismi che regolano l'azione delle cellule staminali nel miocardio ischemico, ma è stato ipotizzato che anche differenze nel tempo di somministrazione delle cellule staminali possano interferire con i dati osservati. A questo proposito i ricercatori dello studio SWiss-AMI [60] hanno dimostrato che il trattamento è più efficace se la somministrazione viene effettuata tra i 4 e i 7 giorni dopo l'IMA, in quanto nelle prime fasi del post-infarto l'ambiente ossidante e l'infiammazione tissutale portano a morte le cellule iniettate e ne riducono l'attecchimento.…”

Section: Cellule Staminaliunclassified

Anti remodeling therapy: new strategies and future perspective in post-ischemic heart failure: Part I

Sirico

Salzano

Celentani

et al. 2015

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

RASSEGNA IntroduzioneGrazie ai recenti miglioramenti delle tecniche di riperfusione coronarica e della terapia farmacologica dell'IMA, negli ultimi anni si è verificato un considerevole aumento della sopravvivenza dei pazienti con questa patologia, anche nei casi più severi [1,2]. Contemporaneamente ciò ha determinato un aumento della morbilità nei pazienti sopravvissuti i quali, in un arco di tempo che va da pochi giorni a diversi mesi, spesso sviluppano disfunzione sistolica e/o diastolica di grado variabile, aritmie maggiori e sintomi da ICC. Questa evoluzione è dovuta al remodeling, un meccanismo fisiopatologico che è stato definito "l'espressione genomica secondaria a danno cardiaco risultante in cambiamenti molecolari, cellulari e interstiziali che si manifestano clinicamente come cambiamenti di dimensione, forma e funzione del cuore" [3]. Come si evince dalla definizione, il remodeling si verifica in seguito a danno cardiaco di qualunque tipo, sia acuto che cronico; tuttavia l'infarto del miocardio ne rappresenta senza dubbio la causa più frequente e pertanto la maggior parte delle ricerche sul remodeling sono state condotte su modelli post-ischemici. Nell'ICC sono numerosi gli studi che stanno cercando testare nuove ipotesi, basate su meccanismi fisiopatologici complementari a quelli classici, nel tentativo di identificare nuovi bersagli terapeutici [4]. Si pensi al modello ormono-metabolico, che da anni si è affacciato nel panorama della ricerca clinica [5,6], date le crescenti evidenze di una connessione molto stretta tre le alterazioni ormonali e il sistema cardiovascolare [7,8]. Tra questi, il remodeling post-infartuale è stato oggetto di studi da oltre un ventennio e, sebbene rimangano numerosi aspetti ampiamente sconosciuti, le scoperte effettuate hanno permesso di progettare e mettere in atto delle strategie terapeutiche volte a contrastare specifiche alterazioni cellulari e molecolari in modo da prevenire le suddette manifestazioni patologiche [9]; come spesso accade in numerose condizioni cliniche [10,11], diversi sono i bersagli cellulari coinvolti, basti pensare alle cellule infiammatorie, In recent years, the remarkable progress achieved in terms of survival after myocardial infarction have led to an increased incidence of chronic heart failure in survivors. This phenomenon is due to the still incomplete knowledge we possess about the complex pathophysiological mechanisms that regulate the response of cardiac tissue to ischemic injury. These involve various cell types such as fibroblasts, cells of the immune system, endothelial cells, cardiomyocytes and stem cells, as well as a myriad of mediators belonging to the system of cytokines and not only. In parallel with the latest findings on post-infarct remodeling, new potential therapeutic targets are arising to halt the progression of disease. In this review, we evaluate the results obtained from four new therapeutic strategies: in this part we evaluate gene therapy and novel aspect of stem cells therapy in remodeling; in the second part we wil...

show abstract

Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI)

Cited by 78 publications

References 32 publications

Intracoronary Injection of Bone Marrow–Derived Mononuclear Cells Early or Late After Acute Myocardial Infarction

Intracoronary Injection of Bone Marrow–Derived Mononuclear Cells Early or Late After Acute Myocardial Infarction

Ex-Vivo Expansion of Cardiac Stem Cell Therapy Products for Clinical Use: The Importance of Moving towards the Optimization of Process Development

Anti remodeling therapy: new strategies and future perspective in post-ischemic heart failure: Part I

Contact Info

Product

Resources

About